Brief: Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold On Lacutamab Clinical Program

Innate Pharma SA

04/01/2024 06:04

Jan 4 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA ANNOUNCES U.S. FDA LIFTS PARTIAL CLINICAL
HOLD ON
LACUTAMAB CLINICAL PROGRAM
    * FATAL CASE RELATED TO DISEASE PROGRESSION AND UNRELATED TO
TREATMENT
    * DEATH OF A PATIENT AFFECTED BY SÉZARY SYNDROME WAS
INITIALLY
CONSIDERED DUE TO HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH), A
RARE HEMATOLOGIC DISORDER.
    * FATAL CASE DETERMINED TO BE RELATED TO AGGRESSIVE DISEASE
PROGRESSION AND LACUTAMAB UNRELATED

Source text for Eikon:  ID:nBw9JTXKha 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))